{"filing":{"accession_number":"0001193125-26-294619","cik":"0001469443","ticker":"RKDA","company_name":"Arcadia Biosciences, Inc.","form":"8-K","filing_date":"2026-07-02","report_date":null,"primary_document":"rkda-20260701.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1469443/000119312526294619/rkda-20260701.htm"},"events":[{"id":15870,"run_id":14156,"accession_number":"0001193125-26-294619","anchor_item_number":"5.02","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"summary":"The Board and Compensation Committee approved a discretionary cash bonus payment of $169,000 to Thomas J. Schaefer, CEO and Interim CFO, for services in 2025, with the updated 2025 Summary Compensation Table reflecting this compensatory arrangement.","company_name":"Arcadia Biosciences, Inc.","ticker":"RKDA","filing_date":"2026-07-02","form":"8-K","submitted_at":null,"items":[{"id":13781,"accession_number":"0001193125-26-294619","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The filing discloses approval by the Board and Compensation Committee on July 1, 2026 of a discretionary cash bonus payment of $169,000 to Thomas J. Schaefer, the CEO and Interim CFO, for services in 2025. The updated 2025 Summary Compensation Table reflects this compensatory arrangement. This is a material disclosure of executive compensation under Item 5.02(f) of Form 8-K, as required by the prior footnote in the Form 10-K/A.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-02T20:23:43.114986+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":15871,"run_id":14156,"accession_number":"0001193125-26-294619","anchor_item_number":"5.08","event_type":"governance_other","event_domain":"governance","is_material":false,"confidence":0.88,"summary":"The Company announced the date of its 2026 annual meeting (September 10, 2026) and provided updated procedural deadlines for stockholder director nominations and proposals due to a \u003e30-day change from the prior year's meeting date.","company_name":"Arcadia Biosciences, Inc.","ticker":"RKDA","filing_date":"2026-07-02","form":"8-K","submitted_at":null,"items":[{"id":13782,"accession_number":"0001193125-26-294619","item_number":"5.08","item_title":"Shareholder Director Nominations","event_type":"governance_other","event_domain":"governance","is_material":false,"confidence":0.92,"reasoning":"This disclosure announces the date of the 2026 annual meeting (September 10, 2026) and provides updated procedural deadlines for stockholder director nominations and proposals due to a \u003e30-day change from the prior year's meeting date. The filing is a routine administrative notice of meeting logistics and shareholder submission deadlines under SEC Rule 14a-8 and the Company's Bylaws, not a material governance event such as an actual director appointment, departure, or shareholder vote result.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-02T20:23:43.114986+00:00","company_name":"","ticker":null,"filing_date":""},{"id":13783,"accession_number":"0001193125-26-294619","item_number":"8.01","item_title":"Other Events.","event_type":"governance_other","event_domain":"governance","is_material":false,"confidence":0.85,"reasoning":"Item 8.01 incorporates by reference information from Item 5.08 regarding the 2026 Annual Meeting, stockholder nomination deadlines, and proxy statement procedures. This is a routine governance disclosure concerning shareholder meeting logistics and nomination procedures, which does not constitute a material event affecting investor assessment of the registrant's financial condition or operations.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-02T20:23:43.114986+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":13781,"accession_number":"0001193125-26-294619","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The filing discloses approval by the Board and Compensation Committee on July 1, 2026 of a discretionary cash bonus payment of $169,000 to Thomas J. Schaefer, the CEO and Interim CFO, for services in 2025. The updated 2025 Summary Compensation Table reflects this compensatory arrangement. This is a material disclosure of executive compensation under Item 5.02(f) of Form 8-K, as required by the prior footnote in the Form 10-K/A.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-02T20:23:43.114986+00:00","company_name":"Arcadia Biosciences, Inc.","ticker":"RKDA","filing_date":"2026-07-02"},{"id":13782,"accession_number":"0001193125-26-294619","item_number":"5.08","item_title":"Shareholder Director Nominations","event_type":"governance_other","event_domain":"governance","is_material":false,"confidence":0.92,"reasoning":"This disclosure announces the date of the 2026 annual meeting (September 10, 2026) and provides updated procedural deadlines for stockholder director nominations and proposals due to a \u003e30-day change from the prior year's meeting date. The filing is a routine administrative notice of meeting logistics and shareholder submission deadlines under SEC Rule 14a-8 and the Company's Bylaws, not a material governance event such as an actual director appointment, departure, or shareholder vote result.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-02T20:23:43.114986+00:00","company_name":"Arcadia Biosciences, Inc.","ticker":"RKDA","filing_date":"2026-07-02"},{"id":13783,"accession_number":"0001193125-26-294619","item_number":"8.01","item_title":"Other Events.","event_type":"governance_other","event_domain":"governance","is_material":false,"confidence":0.85,"reasoning":"Item 8.01 incorporates by reference information from Item 5.08 regarding the 2026 Annual Meeting, stockholder nomination deadlines, and proxy statement procedures. This is a routine governance disclosure concerning shareholder meeting logistics and nomination procedures, which does not constitute a material event affecting investor assessment of the registrant's financial condition or operations.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-02T20:23:43.114986+00:00","company_name":"Arcadia Biosciences, Inc.","ticker":"RKDA","filing_date":"2026-07-02"}]}